Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM101 in Systemic Lupus Erythematosus
DRKS00003248Phase 2Not yet recruiting
- Sponsor
- Suppremol
- Start
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of valziflocept in systemic lupus erythematosus (SLE) (3 arms), sponsored by Suppremol. Primary endpoints: Safety of SM101, Efficacy of SM101 and 1 more. Planned start Sep 2011; status: not yet recruiting.
02
Drugs
valziflocept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on DRKS00003248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003248.